AEGEAN: A phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC - Heymach, JV; Harpole, D; Mitsudomi, T (Cancer Res, 2023)
Abstract CT005